[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autoimmune-thyroid-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autoimmune-thyroid-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100649410","phase-4-fecal-microbiota-transplantation-for-type-2-diabetes-mellitus-and-hashimotos-thyroiditis-100649410",false,"NCT07733232","Fecal Microbiota Transplantation for Type 2 Diabetes Mellitus and Hashimoto's Thyroiditis","Efficacy of Fecal Microbiota Transplantation in Improving Metabolic Parameters and Immune Dysregulation in Patients With Concurrent Type 2 Diabetes Mellitus and Autoimmune Thyroid Disease.","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 65 years old.\n2. Diagnosed with type 2 diabetes mellitus (T2DM).\n3. Positive for thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb); thyroid ultrasonography indicates diffuse thyroid lesions.\n4. The regimens of hypoglycemic drugs and thyroid-related basic treatments (including drug types and dosages) have remained stable for at least 3 months before enrollment.\n\nExclusion Criteria:\n\n1. Subjects who have used antibiotics, probiotics or prebiotics within 4 weeks prior to screening.\n2. Patients complicated with severe gastrointestinal diseases (e.g., inflammatory bowel disease, active gastrointestinal bleeding).\n3. Patients receiving specialized treatment for hyperthyroidism (Graves' disease) or with a history of thyroid malignancy.\n4. Patients with severe immunosuppression (neutrophil count \\\u003C 1500\u002Fmm³, lymphocyte count \\\u003C 500\u002Fmm³).\n5. Patients with active severe gastrointestinal bleeding, intestinal perforation, or severe intestinal barrier\u002Fmucosal injury.\n6. Patients with intestinal mucosal injury of unknown etiology.\n7. Patients diagnosed with fulminant colitis or toxic megacolon.\n8. Patients with active extraintestinal infection requiring treatment with broad-spectrum antibiotics.\n9. Severe malnutrition (body mass index \\\u003C 15 kg\u002Fm²) or severe hypoalbuminemia (serum albumin \\\u003C 25 g\u002FL).\n10. Congenital or acquired immunodeficiency diseases.\n11. Patients who have recently received high-risk immunosuppressants or cytotoxic drugs (e.g., rituximab, doxorubicin), or medium-to-high dose glucocorticoids (e.g., prednisone \\>= 20 mg per day for more than 4 consecutive weeks).\n12. Patients complicated with other autoimmune diseases.\n13. Patients with severe hepatic or renal insufficiency.\n14. Patients with malignant tumors.\n15. Patients with known allergy to capsule ingredients.\n16. Pregnant or lactating females.","ALL","18 Years","65 Years",{"count":20,"type":21},38,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if fecal microbiota transplantation (FMT) can improve metabolic control and immune function in adults with both type 2 diabetes and Hashimoto's thyroiditis (an autoimmune thyroid disease). It will also learn about the safety of FMT in these patients. The main questions it aims to answer are:\n\nCan FMT lower blood sugar levels (HbA1c, fasting blood glucose, and 2-hour post-meal blood glucose) in participants with type 2 diabetes? Can FMT reduce thyroid autoantibody levels (TPOAb and TgAb) in participants with Hashimoto's thyroiditis? This is a single-arm study, meaning all participants will receive the same FMT treatment. Researchers will compare each participant's results before and after the intervention to see if FMT has an effect.\n\nParticipants will:\n\nComplete baseline tests including blood work and stool sample collection during the 2-week screening period Take 40 oral FMT capsules by mouth over about 1.5 hours under medical supervision at the start of the study Keep taking their usual diabetes and thyroid medications at the same dose throughout the study, unless their doctor says otherwise Return for follow-up visits and tests at 12 weeks and 24 weeks after the FMT treatment",[27,28,29],"Autoimmune Thyroid Disease","Type 2 Diabetes Mellitus (T2DM)","FMT","NOT_YET_RECRUITING","2026-07-23",{"date":33,"type":34},"2026-07-29","ACTUAL",{"date":36,"type":21},"2026-08",{"date":38,"type":21},"2027-12",{"name":40,"class":41},"Shen Xujun","OTHER_GOV",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100630961","risk-assessment-of-pancreatic-islet-autoimmunity-in-patients-with-aitd-100630961","NCT07494474","Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD","Autoimmune Thyroid Disease Patients Identification and Assessment of Pancreatic Islet Autoimmune Risk","Inclusion criteria：\n\n1. Voluntary participation and signed informed consent\n2. Age 18-60 years\n3. Diagnosed with autoimmune thyroid disease, with positivity for at least one autoantibody: TPOAb, TgAb, TRAb, or TSI Exclusion criteria：\n\n1: Previously diagnosed diabetes mellitus or current diabetes treatment 2: Conditions severely affecting glucose metabolism (e.g., Cushing's syndrome, acromegaly) 3: Use of immunosuppressants or high-dose glucocorticoids within the past 3 months 4: Pregnancy or lactation 5: Severe cardiac, hepatic, or renal dysfunction, or any condition unsuitable for participation","60 Years",{"count":51,"type":21},834,"2 Months","OBSERVATIONAL","This study aims to evaluate the risk of islet autoimmunity in patients with autoimmune thyroid disease (AITD), describe related clinical and laboratory characteristics, and explore the development of a risk assessment model based on clinical, laboratory, and genetic markers. Adults aged 18-60 years with confirmed AITD will undergo baseline assessment including demographic data, anthropometric measures, lifestyle factors, medical history, thyroid-related clinical information, thyroid function, and thyroid antibody testing. A baseline blood sample will be collected for measurement of islet autoantibodies (GADA, IA-2A, ZnT8A, and IAA). Participants with positive islet autoantibodies will undergo further evaluation of glucose metabolism and beta-cell function, including HbA1c, OGTT, insulin, and C-peptide testing. Genome-wide genetic data will be used to construct a type 1 diabetes-related genetic risk score, and additional HLA genotyping may be performed in autoantibody-positive participants. The study will assess the prevalence and profile of islet autoantibodies in AITD and identify clinical, laboratory, and genetic factors associated with islet autoantibody positivity.",[27],[57,58,59],"AITD","Islet autoantibodies","type 1 diabetes","2026-03-20",{"date":62,"type":34},"2026-03-27",{"date":64,"type":21},"2026-08-31",{"date":66,"type":21},"2028-04-30",{"name":68,"class":69},"Nanjing Medical University","OTHER",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100587208","changes-in-natural-immunity-in-pregnant-women-with-autoimmune-thyroid-disease-100587208","NCT06925399","Changes in Natural Immunity in Pregnant Women With Autoimmune Thyroid Disease","Dynamic Changes of Innate Immune Cells in Pregnant Women With Autoimmune Thyroid Disease","CIPAT","Inclusion Criteria: adult healthy pregnant women and pregnant women with autoimmune thyroid disease\n\n* with a single pregnancy\n* older than 18 years\n* who have signed the informed consent form\n\nExclusion Criteria:\n\n* pregnant women who refuse to give informed consent\n* pregnant women under the age of 18\n* pregnant women with malignant diseases\n* pregnant women with thyrotoxicosis or hypothyroidism of a non-autoimmune nature and previous thyroidectomy or ablative therapy with iodine-131\n* pregnant women with an acute or chronic disease that is not an autoimmune thyroid disease","FEMALE","45 Years",{"count":81,"type":21},80,"Autoimmune thyroid disease (AITD) is the most common endocrine disorder in women of reproductive age, including during pregnancy. It encompasses two clinical conditions: autoimmune hyperthyroidism and hypothyroidism. Pregnancy significantly affects thyroid function regulation, while thyroid dysfunction can influence fertility, pregnancy progression, and the postpartum health. Although the role of acquired immunity in AITD is well understood, recent research increasingly emphasizes innate immunity. Key cells involved in innate immunity include neutrophils, monocytes, and NKT cells. However, limited data exist on their role during pregnancy, especially in women with AITD.\n\nThis study aims to investigate the dynamic changes in neutrophils, monocytes and NKT cells during pregnancy and compare findings between women with normal pregnancies and those with AITD.\n\nThe study will analyze the frequency and activation status of these innate immune cells in peripheral blood samples collected during the first, second, and third trimesters. In addition, concentrations of thyrotropin, thyroid hormones, thyroglobulin, and thyroid autoantibodies, will be measured. A thyroid ultrasound will also be performed.",[84,27],"Pregnancy",[84,86,87,88,89,90],"Autoimmune thyroid disease","Innate immunity","NKT cells","Monocytes","Neutrophils","2025-04-06",{"date":93,"type":34},"2025-04-13",{"date":95,"type":21},"2025-05-01",{"date":97,"type":21},"2027-05-01",{"name":99,"class":69},"University of Rijeka",1]